Scar

Dermatology·MeSH: Cicatrix

16 drugs in development·14 companies·3 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
cobenfy	BRISTOL MYERS SQUIBB CO (BMY)
dicyclomine	NEXUS BIOPHARMA INC (NEXS)
glycopyrrolate	Amneal Pharmaceuticals, Inc. (AMRX)
olpruva	Acer Therapeutics Inc. (ACER)
skinstylus sterilock microsystem	The Beauty Health Company (SKIN)
tri-heart plus chewable	HESKA CORP (HSKA)
vuity	AbbVie Inc. (ABBV)
vyalev	AbbVie Inc. (ABBV)

Phase 3(2)

Drug	Company
DMT410	Dermata Therapeutics Inc. (DRMA)
rgn-137	REGENERX BIOPHARMACEUTICALS INC (RGRX)

Preclinical(2)

Drug	Company
p-otc-101	Poseida Therapeutics, Inc. (PSTX)
prx-otc	PHASERX, INC. (PZRX)

Phase 1/Phase 2(1)

Drug	Company
ecur-506	PRECISION BIOSCIENCES INC (DTIL)

Phase 2/Phase 3(2)

Drug	Company
ip1 control	Q BioMed Inc. (QBIO)
ip2 - 0.5% w/w fs2	Q BioMed Inc. (QBIO)

Phase 4(1)

Drug	Company
Botulinum Toxins	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 16 drugs in development for Scar across 14 companies.

There are 3 clinical trials targeting Scar tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.